Posts

Showing posts with the label Liver Fibrosis market forecast

Liver Fibrosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Liver fibrosis, an ineffective wound-healing process in the liver triggered by repeated and chronic injury from various causes such as infectious diseases (e.g., viral hepatitis), metabolic disorders (like nonalcoholic steatohepatitis), exposure to toxins (such as alcohol liver diseases), or autoimmune conditions (e.g., primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis), is characterized by the accumulation of extracellular matrix (ECM) produced by myofibroblasts. In healthy livers, myofibroblasts are absent but accumulate in response to injury, serving as the primary effector cells in fibrogenesis. Crucial events in the pathogenesis of liver fibrosis include hepatocyte damage triggering inflammatory reactions and the subsequent activation of hepatic stellate cells (HSCs), which in their quiescent state in normal livers store retinoids and function as pericytes for sinusoidal endothelial cells. In March 2024, the FDA approved Rezdiffra (resmeti...

Liver Fibrosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
  Liver fibrosis is an ineffective wound-healing process of the liver in response to repeated and chronic injury from many etiologies, such as infectious diseases like viral hepatitis, metabolic derangements (non-alcoholic steatohepatitis), exposure to toxins (e.g., alcohol liver diseases), or autoimmune diseases (e.g., primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis). The morphology characteristics of liver fibrosis are the deposition of extracellular matrix (ECM) produced by myofibroblasts. Myofibroblasts are absent from the healthy liver, accumulate in the injured liver, and serve as the principal effector cells of fibrogenesis. Several events are critical for the pathogenesis of liver fibrosis and its resolution. Damage to hepatocytes causes inflammatory reactions, which lead to the activation of hepatic stellate cells (HSCs). HSCs in the normal liver are in a quiescent state and function to store retinoids and serve as the pericytes for the ...

Liver Fibrosis – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
  Liver fibrosis is an ineffective wound-healing process of the liver in response to repeated and chronic injury from many etiologies, such as infectious diseases like viral hepatitis, metabolic derangements (non-alcoholic steatohepatitis), exposure to toxins (e.g., alcohol liver diseases), or autoimmune diseases (e.g., primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis). The morphology characteristics of liver fibrosis are the deposition of extracellular matrix (ECM) produced by myofibroblasts. Myofibroblasts are absent from the healthy liver, accumulate in the injured liver, and serve as the principal effector cells of fibrogenesis. Several events are critical for the pathogenesis of liver fibrosis and its resolution. Damage to hepatocytes causes inflammatory reactions, which lead to the activation of hepatic stellate cells (HSCs). HSCs in the normal liver are in a quiescent state and function to store retinoids and serve as the pericytes for the ...